Akari Therapeutics

AKTX · NASDAQ

$9.29−$0.60 (−6.07%)TodayMarket closed · Oct 20, 6:16 PM ET

Prev close $9.89

AKTX analyst rating

BuyConsensus of 3 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy3
Hold0
Underperform0
Sell0

12-month price target · 6 analysts

Average $29.71 (+219.8% upside)

Low: $19.69
Now: $9.29
High: $42.00

Upgrades and downgrades

The latest rating actions, newest first

AKTX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Maxim Group	Jul 20, 2026	Upgrade	Hold → Buy	$30.00	27%
Maxim Group	Apr 8, 2026	Downgrade	Buy → Hold	—	27%
HC Wainwright & Co.	Apr 1, 2026	Maintains	Buy	$1.60 → $27.00	42%
Ladenburg Thalmann	Jan 5, 2026	Initiates	Buy	$1.00	32%

The case for and against

Updated Feb 9, 2026

Bull case

Akari Therapeutics PLC is developing AKTX-101, a preclinical stage Trop2-targeting antibody-drug conjugate (ADC) that has shown promising preclinical efficacy against bladder and gastric cancers, particularly in combination with immuno-oncology agents. The preclinical data suggests that AKTX-101 not only demonstrates significant anti-tumor activity but also potentially generates immunological memory, enhancing long-term protection against tumor rechallenge. The novel ADC platform may lead to best-in-class therapeutic outcomes, especially when integrated with existing immunotherapies, which positions Akari favorably within the oncology landscape.

Bear case

Akari Therapeutics PLC presents a promising ADC platform; however, its weak balance sheet poses a significant risk that could negatively impact investor sentiment. The potential financial overhang is expected to weigh on the stock, particularly as the company seeks to secure additional funding for its ongoing and planned preclinical and clinical programs. Until such funding is obtained, continued concerns regarding financial stability may hinder the company's stock performance.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.